NASDAQ:RARE

Ultragenyx Pharmaceutical Competitors

$108.72
-0.86 (-0.78 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$107.66
Now: $108.72
$110.73
50-Day Range
$100.53
MA: $118.69
$142.47
52-Week Range
$54.73
Now: $108.72
$179.65
Volume378,406 shs
Average Volume454,731 shs
Market Capitalization$7.28 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.19

Competitors

Ultragenyx Pharmaceutical (NASDAQ:RARE) Vs. BGNE, RPRX, GMAB, HZNP, CVAC, and CTLT

Should you be buying RARE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Ultragenyx Pharmaceutical, including BeiGene (BGNE), Royalty Pharma (RPRX), Genmab A/S (GMAB), Horizon Therapeutics Public (HZNP), CureVac (CVAC), and Catalent (CTLT).

Ultragenyx Pharmaceutical (NASDAQ:RARE) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Insider and Institutional Ownership

60.7% of BeiGene shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 9.0% of BeiGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Profitability

This table compares Ultragenyx Pharmaceutical and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%
BeiGene-569.22%-56.81%-39.93%

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and BeiGene's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million70.18$-402,730,000.00($7.36)-14.77
BeiGene$428.21 million65.43$-948,630,000.00($15.80)-19.34

Ultragenyx Pharmaceutical has higher earnings, but lower revenue than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ultragenyx Pharmaceutical and BeiGene, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical06802.57
BeiGene21602.44

Ultragenyx Pharmaceutical presently has a consensus price target of $131.20, indicating a potential upside of 20.68%. BeiGene has a consensus price target of $319.3750, indicating a potential upside of 4.53%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than BeiGene.

Summary

Ultragenyx Pharmaceutical beats BeiGene on 10 of the 14 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Insider and Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 2.5% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Ultragenyx Pharmaceutical and Royalty Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%
Royalty PharmaN/AN/AN/A

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and Royalty Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million70.18$-402,730,000.00($7.36)-14.77
Royalty PharmaN/AN/AN/AN/AN/A

Royalty Pharma has lower revenue, but higher earnings than Ultragenyx Pharmaceutical.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ultragenyx Pharmaceutical and Royalty Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical06802.57
Royalty Pharma05402.44

Ultragenyx Pharmaceutical presently has a consensus price target of $131.20, indicating a potential upside of 20.68%. Royalty Pharma has a consensus price target of $51.8750, indicating a potential upside of 23.90%. Given Royalty Pharma's higher probable upside, analysts clearly believe Royalty Pharma is more favorable than Ultragenyx Pharmaceutical.

Summary

Royalty Pharma beats Ultragenyx Pharmaceutical on 5 of the 9 factors compared between the two stocks.

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Volatility and Risk

Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ultragenyx Pharmaceutical and Genmab A/S, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ultragenyx Pharmaceutical06802.57
Genmab A/S24802.43

Ultragenyx Pharmaceutical presently has a consensus price target of $131.20, indicating a potential upside of 20.68%. Genmab A/S has a consensus price target of $42.1429, indicating a potential upside of 19.62%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Genmab A/S.

Insider and Institutional Ownership

6.2% of Genmab A/S shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ultragenyx Pharmaceutical and Genmab A/S's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$103.71 million70.18$-402,730,000.00($7.36)-14.77
Genmab A/S$804.57 million28.72$324.68 million$0.5169.08

Genmab A/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ultragenyx Pharmaceutical and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%
Genmab A/S50.99%34.40%30.67%

Summary

Genmab A/S beats Ultragenyx Pharmaceutical on 8 of the 13 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares Horizon Therapeutics Public and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Risk and Volatility

Horizon Therapeutics Public has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Horizon Therapeutics Public and Ultragenyx Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public001103.00
Ultragenyx Pharmaceutical06802.57

Horizon Therapeutics Public presently has a consensus target price of $111.3636, indicating a potential upside of 19.40%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, indicating a potential upside of 20.68%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Horizon Therapeutics Public.

Insider and Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by company insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Horizon Therapeutics Public and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion16.08$573.02 million$1.9448.08
Ultragenyx Pharmaceutical$103.71 million70.18$-402,730,000.00($7.36)-14.77

Horizon Therapeutics Public has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Summary

Horizon Therapeutics Public beats Ultragenyx Pharmaceutical on 10 of the 14 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Insider & Institutional Ownership

4.3% of CureVac shares are held by institutional investors. 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares CureVac and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for CureVac and Ultragenyx Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11202.25
Ultragenyx Pharmaceutical06802.57

CureVac currently has a consensus target price of $58.3333, indicating a potential downside of 46.63%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, indicating a potential upside of 20.68%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than CureVac.

Valuation & Earnings

This table compares CureVac and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical$103.71 million70.18$-402,730,000.00($7.36)-14.77

CureVac has higher earnings, but lower revenue than Ultragenyx Pharmaceutical.

Summary

Ultragenyx Pharmaceutical beats CureVac on 5 of the 9 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Catalent and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Volatility and Risk

Catalent has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.

Insider and Institutional Ownership

97.8% of Catalent shares are owned by institutional investors. 1.0% of Catalent shares are owned by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Catalent and Ultragenyx Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion6.08$173 million$1.8858.83
Ultragenyx Pharmaceutical$103.71 million70.18$-402,730,000.00($7.36)-14.77

Catalent has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Catalent and Ultragenyx Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Ultragenyx Pharmaceutical06802.57

Catalent currently has a consensus target price of $125.1250, indicating a potential upside of 13.13%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, indicating a potential upside of 20.68%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Catalent.

Summary

Catalent beats Ultragenyx Pharmaceutical on 9 of the 14 factors compared between the two stocks.


Ultragenyx Pharmaceutical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BeiGene logo
BGNE
BeiGene
1.3$305.54-0.7%$28.02 billion$428.21 million-15.12Analyst Downgrade
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.87-0.5%$25.42 billionN/A0.00Dividend Announcement
Insider Selling
Increase in Short Interest
News Coverage
Genmab A/S logo
GMAB
Genmab A/S
1.4$35.23-0.7%$23.11 billion$804.57 million27.31Decrease in Short Interest
Analyst Revision
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.27-0.3%$20.90 billion$1.30 billion25.48Insider Selling
CureVac logo
CVAC
CureVac
0.6$109.29-4.8%$20.43 billionN/A0.00Analyst Downgrade
Unusual Options Activity
News Coverage
Gap Down
Catalent logo
CTLT
Catalent
1.7$110.60-0.4%$18.83 billion$3.09 billion70.45Unusual Options Activity
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.88-0.1%$16.29 billion$219.75 million-17.74
Zai Lab logo
ZLAB
Zai Lab
1.4$164.29-0.4%$14.55 billion$12.98 million-54.22Analyst Report
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$79.40-0.8%$14.44 billion$1.70 billion18.17News Coverage
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$29.98-0.7%$14.17 billion$3.07 billion-52.60Analyst Report
Grifols logo
GRFS
Grifols
1.3$17.98-1.6%$12.36 billion$5.71 billion16.05Upcoming Earnings
News Coverage
Gap Up
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.75-0.7%$11.74 billion$16.89 billion-2.92Decrease in Short Interest
News Coverage
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$65.01-1.4%$10.81 billion$2.32 billion53.73
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.03-0.9%$10.68 billion$8.60 billion-5.51
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.90-0.3%$9.51 billion$2.16 billion53.28Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.68-0.1%$9.45 billionN/A0.00Increase in Short Interest
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.73-1.0%$9.07 billion$1.45 billion19.27Analyst Report
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$55.12-0.3%$8.21 billion$40.56 million-16.16
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$158.19-3.7%$8.01 billion$3.34 million-20.54Unusual Options Activity
News Coverage
Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.65-0.5%$7.02 billion$87.99 million-80.54News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90-0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$121.95-1.8%$6.55 billion$14.98 million-14.85Analyst Downgrade
News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.78-2.3%$6.30 billion$150,000.00-21.12High Trading Volume
Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78-0.6%$5.74 billion$1.12 billion84.96Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80-1.2%$5.70 billion$380.83 million-9.18Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.3$41.62-1.1%$5.56 billion$4.84 billion-693.55
Allakos logo
ALLK
Allakos
1.7$104.50-3.5%$5.55 billionN/A-38.14Insider Selling
Gap Down
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20-0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.3$77.90-0.6%$5.45 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15-0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40-1.9%$4.62 billionN/A-6.06Analyst Revision
Gap Down
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.64-1.2%$4.36 billion$6.87 million-7.21Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25-0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
Gap Up
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69-0.6%$3.82 billion$117.91 million-11.09News Coverage
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94-2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57-1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03-5.8%$3.58 billionN/A-20.81Analyst Report
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
LEGN
Legend Biotech
1.2$26.00-0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.59-0.8%$3.42 billion$306.98 million-6.95News Coverage
Insmed logo
INSM
Insmed
1.2$33.07-1.7%$3.42 billion$136.47 million-12.72News Coverage
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.15-0.2%$3.38 billion$339.08 million-12.30Analyst Report
High Trading Volume
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87-1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46News Coverage
Gap Down
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19Insider Selling
Arvinas logo
ARVN
Arvinas
1.5$64.69-2.6%$3.16 billion$42.98 million-25.27Analyst Upgrade
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60-4.2%$3.04 billionN/A-56.02Insider Selling
Gap Down
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.